QQQ   418.07 (-1.26%)
AAPL   165.13 (-1.14%)
MSFT   401.05 (-0.80%)
META   485.91 (-3.17%)
GOOGL   154.54 (-0.94%)
AMZN   175.54 (-2.05%)
TSLA   148.64 (-0.86%)
NVDA   796.73 (-5.90%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.96 (+0.12%)
T   16.41 (+0.49%)
F   12.13 (+0.58%)
MU   107.36 (-4.08%)
GE   149.59 (-2.19%)
CGC   8.12 (+3.70%)
DIS   112.30 (-0.12%)
AMC   3.23 (+10.62%)
PFE   25.83 (+1.73%)
PYPL   62.18 (+0.13%)
XOM   119.99 (+1.24%)
QQQ   418.07 (-1.26%)
AAPL   165.13 (-1.14%)
MSFT   401.05 (-0.80%)
META   485.91 (-3.17%)
GOOGL   154.54 (-0.94%)
AMZN   175.54 (-2.05%)
TSLA   148.64 (-0.86%)
NVDA   796.73 (-5.90%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.96 (+0.12%)
T   16.41 (+0.49%)
F   12.13 (+0.58%)
MU   107.36 (-4.08%)
GE   149.59 (-2.19%)
CGC   8.12 (+3.70%)
DIS   112.30 (-0.12%)
AMC   3.23 (+10.62%)
PFE   25.83 (+1.73%)
PYPL   62.18 (+0.13%)
XOM   119.99 (+1.24%)
QQQ   418.07 (-1.26%)
AAPL   165.13 (-1.14%)
MSFT   401.05 (-0.80%)
META   485.91 (-3.17%)
GOOGL   154.54 (-0.94%)
AMZN   175.54 (-2.05%)
TSLA   148.64 (-0.86%)
NVDA   796.73 (-5.90%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.96 (+0.12%)
T   16.41 (+0.49%)
F   12.13 (+0.58%)
MU   107.36 (-4.08%)
GE   149.59 (-2.19%)
CGC   8.12 (+3.70%)
DIS   112.30 (-0.12%)
AMC   3.23 (+10.62%)
PFE   25.83 (+1.73%)
PYPL   62.18 (+0.13%)
XOM   119.99 (+1.24%)
QQQ   418.07 (-1.26%)
AAPL   165.13 (-1.14%)
MSFT   401.05 (-0.80%)
META   485.91 (-3.17%)
GOOGL   154.54 (-0.94%)
AMZN   175.54 (-2.05%)
TSLA   148.64 (-0.86%)
NVDA   796.73 (-5.90%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.96 (+0.12%)
T   16.41 (+0.49%)
F   12.13 (+0.58%)
MU   107.36 (-4.08%)
GE   149.59 (-2.19%)
CGC   8.12 (+3.70%)
DIS   112.30 (-0.12%)
AMC   3.23 (+10.62%)
PFE   25.83 (+1.73%)
PYPL   62.18 (+0.13%)
XOM   119.99 (+1.24%)
Free Trial

Compare Stocks

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BTC
ClearShares Piton Intermediate Fixed Income ETF
$90.46
-0.2%		$91.64
$98.48
▼
$100.89
$29.40MN/A1,456 shs402 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$9.06
-1.3%		$8.70
$2.80
▼
$8.97
$326.69M0.6337,931 shs456,563 shs
The 10 Best AI Stocks to Own in 2024 Cover
The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BTC
ClearShares Piton Intermediate Fixed Income ETF
+0.31%+0.01%-1.16%-1.41%-8.55%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00%-2.27%+7.09%+49.01%+37.27%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BTC
ClearShares Piton Intermediate Fixed Income ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BTC
ClearShares Piton Intermediate Fixed Income ETF
0.00
N/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BTC
ClearShares Piton Intermediate Fixed Income ETF
N/AN/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BTC
ClearShares Piton Intermediate Fixed Income ETF
N/AN/A0.00∞N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BTC
ClearShares Piton Intermediate Fixed Income ETF
$0.020.02%N/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BTC
ClearShares Piton Intermediate Fixed Income ETF
N/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BTC
ClearShares Piton Intermediate Fixed Income ETF
N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%

Insider Ownership

CompanyInsider Ownership
BTC
ClearShares Piton Intermediate Fixed Income ETF
N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BTC
ClearShares Piton Intermediate Fixed Income ETF
147,000325,000N/ANot Optionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

SBTX, BTC, CDY, 1AD, and DEST Headlines

SourceHeadline
Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2%Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2%
marketbeat.com - April 3 at 2:15 AM
ARS Pharmaceuticals Inc (SPRY)ARS Pharmaceuticals Inc (SPRY)
uk.investing.com - May 11 at 1:32 PM
Wild IslesWild Isles
wwf.org.uk - March 12 at 9:31 AM
A look back at RNA Therapeutics – day oneA look back at RNA Therapeutics – day one
pharmaphorum.com - February 24 at 12:35 AM
SPRY ARS Pharmaceuticals, Inc.SPRY ARS Pharmaceuticals, Inc.
seekingalpha.com - January 24 at 8:04 PM
ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger
247wallst.com - November 22 at 6:29 AM
Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsDr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics
nasdaq.com - November 18 at 8:19 PM
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
finance.yahoo.com - November 10 at 6:41 PM
ARS Pharmaceuticals Closes Merger with Silverback TherapeuticsARS Pharmaceuticals Closes Merger with Silverback Therapeutics
finance.yahoo.com - November 8 at 5:59 PM
Silverback : FDA Accepts ARS Pharms NDA For Neffy For Treatment Of Allergic ReactionsSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions
markets.businessinsider.com - October 28 at 8:15 AM
FDA accepts ARS Pharma’s NDA for NeffyFDA accepts ARS Pharma’s NDA for Neffy
thepharmaletter.com - October 24 at 10:29 AM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERISHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI
kentuckytoday.com - October 23 at 7:22 PM
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
finance.yahoo.com - October 21 at 7:59 AM
Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?
aaii.com - October 19 at 11:52 AM
SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNSHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN
bakersfield.com - October 12 at 11:07 PM
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
markets.businessinsider.com - September 17 at 5:10 AM
SBTX Silverback Therapeutics, Inc.SBTX Silverback Therapeutics, Inc.
seekingalpha.com - September 15 at 10:58 PM
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT
markets.businessinsider.com - September 6 at 11:53 AM
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
markets.businessinsider.com - August 23 at 6:32 PM
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTXSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTX
apnews.com - August 17 at 12:02 PM
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTXSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTX
apnews.com - August 11 at 1:33 AM
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing InvestigationsSHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations
morningstar.com - July 30 at 7:00 AM
INVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYINVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
apnews.com - July 28 at 2:21 AM
Shareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTXShareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTX
benzinga.com - July 27 at 9:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

ClearShares Piton Intermediate Fixed Income ETF

NYSEARCA:BTC
Silverback Therapeutics logo

Silverback Therapeutics

NASDAQ:SBTX
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.